A three-amino-acid fragment of alpha-MSH studied in animals for anti-inflammatory effects in the gut and skin.
KPV is the last three amino acids (lysine-proline-valine) of alpha-melanocyte-stimulating hormone. Unlike full alpha-MSH, it is not associated with tanning, and research has focused on its anti-inflammatory activity.
KPV is not an FDA-approved drug. In July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend adding it to the 503A bulks list. The vote is non-binding and FDA has not finalized it.
Status reflects public FDA actions and reporting as of October 8, 2026. An advisory committee vote is a recommendation, not an FDA decision, and inclusion on a compounding list is not FDA approval.
Studies in mice with induced colitis and in cell models report reduced inflammation. Controlled human trials have not been published.
nnng.com does not publish doses, cycles or protocols for peptides. For approved drugs, the dose comes from the FDA-approved prescribing information and your prescriber. For unapproved compounds there is no established human dose, and numbers that circulate online are usually extrapolated from animal studies or written by sellers. If a clinician has already prescribed a dose, our reconstitution calculator converts that prescribed amount into syringe units. It is arithmetic only and does not suggest a dose.